The first complaint is almost always burning. A client tells you that her scalp itches, that it hurts when she brushes, that there is a tender, almost sunburned feeling along the part line. The hair is shedding, but not in the diffuse way a telogen effluvium sheds. There are small, smooth bald spots scattered through the crown that look as if someone reached in with a tiny eraser. The skin within those spots is paler and shinier than the surrounding scalp, and the follicular openings are gone. She has been treating this with tea tree shampoo and a B-vitamin for six months. She is forty-one years old. What she actually has is lichen planopilaris, an immune-mediated, lymphocytic, primary scarring alopecia that has already permanently deleted some of the follicles she came in to save.
LPP is the disease most likely to be missed. Unlike CCCA, which has a stereotyped vertex distribution, and unlike FFA, which announces itself at the hairline, classic LPP can erupt anywhere on the scalp, can mimic androgenetic alopecia in its earliest stages, and can be active for months under the radar of routine evaluation. The painful, burning, itching prodrome is a major diagnostic clue, but many clients normalize it, and many practitioners do not ask about it.
This is what the peer-reviewed literature actually says about LPP in 2026: what the disease is, what the immune mechanism looks like at the bulge, how the LPPAI quantifies disease activity, and what the treatment data — from hydroxychloroquine and pioglitazone through low-dose naltrexone and tofacitinib — supports for a clinical ladder.
What LPP Actually Is
LPP is a primary lymphocytic cicatricial alopecia. Translation: the immune system targets the upper portion of the hair follicle, the inflammatory infiltrate destroys the follicular stem cell reservoir in the bulge region, and the follicle is replaced by fibrous scar tissue. Once a follicle is fibrosed, it is gone. The disease lives on a spectrum with frontal fibrosing alopecia (FFA), which most authors now consider a clinical variant of LPP, and with Graham-Little-Piccardi-Lasseur syndrome, a rarer triad of scalp LPP, non-scarring loss of body and pubic hair, and follicular keratotic papules.
LPP is broadly subclassified into three clinical phenotypes, which most reviews still treat as the operative framework:
Classic LPP is the prototype: scattered patches of cicatricial alopecia anywhere on the scalp, usually with a parietal-vertex predilection, accompanied by perifollicular erythema and perifollicular scale at the active edges. Symptoms of pruritus, burning, tenderness, and trichodynia are reported in the majority of patients. Onset is usually mid-adulthood and the female-to-male ratio is roughly 2:1 to 4:1 across series.
Frontal fibrosing alopecia is the band-like recession of the frontal and frontotemporal hairline, with eyebrow and body hair involvement, in a strikingly female and largely postmenopausal demographic. (We covered FFA in detail in post 26.) Histopathologically and mechanistically it is essentially LPP at a different location.
Graham-Little-Piccardi-Lasseur syndrome is the classical triad: scarring scalp alopecia of the LPP type, non-scarring axillary and pubic hair loss, and disseminated keratosis pilaris-like follicular spinous papules on the trunk and limbs. Rare, but worth recognizing in any patient with cicatricial scalp loss accompanied by unusual body-hair patterns.
A fourth clinical entity, fibrosing alopecia in a pattern distribution (FAPD), was first described by Zinkernagel and Trueb in 2000. FAPD looks like androgenetic alopecia at first glance, with thinning over the central crown in the typical pattern, but trichoscopy and biopsy reveal cicatricial features — perifollicular erythema, perifollicular scale, and lichenoid interface change. FAPD blurs the line between AGA and LPP and is the reason every progressive female central thinning case deserves a second look.
The Mechanism: Loss of Immune Privilege at the Bulge
The healthy hair follicle maintains constitutive immune privilege at the bulge, the region where the follicular stem cells live. The bulge keeps MHC class I expression suppressed, expresses local immunosuppressants, and hides its stem cell antigens from the adaptive immune system. Immune privilege is what allows the follicle to cycle for decades without being destroyed by the body’s own surveillance. When that privilege collapses, the stem cells are exposed, and the follicle becomes a target.
In LPP, the immune privilege collapse is mediated by a Th1-skewed CD8+ T-cell response. IFN-γ is the central cytokine. It drives aberrant MHC class I upregulation on the bulge epithelium, recruits cytotoxic T cells, and amplifies a JAK1/JAK3-STAT1 signaling cascade. The histopathologic correlate is a lichenoid interface dermatitis at the upper follicle, with the lymphocytic infiltrate hugging the isthmus and infundibulum where the stem cells and the sebaceous gland live. The sebaceous gland is consistently among the first structures to disappear, and its loss is part of what makes LPP and its variants different from non-scarring alopecias.
One of the most important mechanistic findings of the last fifteen years is the role of peroxisome proliferator-activated receptor gamma (PPAR-γ). Karnik and colleagues at Penn published a 2009 paper in the Journal of Investigative Dermatology showing that PPAR-γ signaling is selectively downregulated in LPP biopsies and that conditional deletion of PPAR-γ in mouse follicular stem cells reproduces a scarring alopecia clinically and histologically resembling LPP. The implication is that the upper follicle and the sebaceous gland depend on PPAR-γ for lipid metabolism and anti-inflammatory tone, and that loss of PPAR-γ activity is part of what makes the upper follicle vulnerable to the lichenoid attack. The pioglitazone trials that followed are the direct clinical translation of that finding.
The Lichen Planopilaris Activity Index
For a long time the LPP literature was a series of small case series with no shared way of measuring disease activity. Chiang and colleagues at Stanford solved that problem with the Lichen Planopilaris Activity Index. The LPPAI is a composite score that captures the active inflammatory features of LPP at a single visit and lets practitioners compare a patient to herself across time, and lets investigators compare treatments to each other.
The score combines symptoms (pruritus, pain, burning) on a 0–3 scale, clinical signs (scalp erythema, perifollicular erythema, perifollicular scale) on a 0–3 scale, hair pull test (positive or negative), and the presence of anagen hairs in the pull. The result is a composite score from 0 to a theoretical maximum that distinguishes active disease from quiescent disease and lets you watch the score fall as therapy works. A reduction of at least 85% in the LPPAI is generally accepted as meaningful clinical improvement in subsequent literature.
The original Chiang 2010 study itself reported on 40 LPP patients treated with hydroxychloroquine 200 mg twice daily, evaluated at 6 and 12 months. By 6 months, 69% of patients had a significant reduction in their LPPAI. By 12 months, 83% had a significant reduction. The hydroxychloroquine evidence base for LPP largely starts here, and the LPPAI itself has become the de facto outcome measure across nearly every retrospective study and small trial published in LPP since.
Diagnosis: What Trichologists Should Recognize
The diagnostic logic for LPP rests on three layers: history, trichoscopy, and biopsy. Each layer narrows the differential and each is something a trained trichologist can advance even when biopsy ultimately requires a dermatologist.
History. Burning, itching, painful tenderness, and trichodynia (the sensation that the hair itself hurts to touch) are reported in the majority of LPP patients and are the single most important screening question. A client with progressive central scalp thinning who also describes these symptoms is not a presumptive AGA; she is a presumptive scarring alopecia until proven otherwise. Onset is usually gradual but can be subacute. Family history of lichen planus, oral lichen planus, or nail lichen planus is relevant: roughly 30–50% of LPP patients have or develop extracutaneous lichen planus elsewhere.
Trichoscopy. The findings that point toward LPP are loss of follicular ostia, perifollicular erythema, perifollicular scale forming concentric “tubular” or “collar” configurations around emerging hairs, and white dots representing fibrotic tracts where follicles used to be. The combination of perifollicular erythema with perifollicular scale at active patch edges is highly suggestive. Compare this to non-scarring loss, where ostia remain visible and the surface is normal. A trichoscope is the single most useful piece of equipment a trichologist can own, and LPP is one of the diseases that justifies the investment most clearly.
Biopsy. A 4 mm punch biopsy taken from an active patch edge — not from the central scarred area — remains the diagnostic gold standard. Histopathology shows a lichenoid interface dermatitis at the upper follicle, perifollicular lymphocytic infiltrate hugging the isthmus and infundibulum, perifollicular fibrosis, and absent or atrophic sebaceous glands. Direct immunofluorescence is generally negative or non-specific. Two horizontal-section biopsies are often more informative than one vertical-section biopsy because horizontal sections give simultaneous visualization of multiple follicles at all anatomic levels.
The single most impactful thing a trichologist can do for a suspected LPP client is to recognize the symptom-plus-perifollicular-erythema pattern and refer to a dermatologist within weeks rather than months. In LPP, every month of unrecognized active disease costs follicles. Document the trichoscopic findings, photograph the active edges, capture the LPPAI symptoms in your intake notes, and write a referral letter that names the suspicion. Dermatologists triage faster when the referral is specific.
Treatment: The Evidence-Based Ladder
First-line systemic: Hydroxychloroquine
Chiang 2010 established the modern evidence base for hydroxychloroquine in LPP. Subsequent retrospective series have replicated the finding: HCQ at 200 mg twice daily produces meaningful LPPAI reduction in roughly 60–75% of patients across pooled data. It is generally well tolerated. The principal monitoring requirement is annual ophthalmologic screening for retinal toxicity, which becomes a more pressing issue at higher cumulative doses and after five years of continuous therapy. The 2024 FFA finasteride-versus-hydroxychloroquine RCT (Saber et al, J Cosmet Dermatol) further reinforced the role of HCQ across the LPP/FFA spectrum.
Second-line: Pioglitazone
Pioglitazone, the PPAR-γ agonist used in type 2 diabetes, was repurposed for LPP on the strength of Karnik’s mechanism paper. Mesinkovska and the Cleveland Clinic group reported a small series in 2015 in JAAD showing meaningful clinical response in LPP patients treated with 15 mg daily, and Spring and colleagues followed in JAAD 2013 with a series demonstrating decreased LPPAI and decreased symptoms. Subsequent retrospective work has been mixed: Mirmirani in 2016 reported high relapse rates and a low rate of sustained complete response, and the FDA black-box warning on bladder cancer risk with long-term high-dose pioglitazone has tempered enthusiasm. In 2024–2025 reviews, pioglitazone retains a defensible second-line role in HCQ-refractory LPP, with informed consent about the risk profile, and is a particularly logical choice in patients with concomitant insulin resistance.
Adjunct: Doxycycline and topicals
Doxycycline 100 mg twice daily is widely used as an adjunct anti-inflammatory in LPP. Mirmirani and colleagues published the foundational case series on tetracycline-class antibiotics for cicatricial alopecia in Clinical and Experimental Dermatology. The mechanism is anti-inflammatory rather than antimicrobial: matrix metalloproteinase inhibition, modulation of neutrophil function, and reduction of cytokine-driven follicular inflammation. Topical clobetasol propionate, intralesional triamcinolone (5–10 mg/mL injected at active patch edges every 4–6 weeks), and topical tacrolimus or pimecrolimus all have a role in active local inflammation and are commonly layered onto systemic therapy. None of these stop the disease alone. They suppress local inflammatory activity while the systemic agent works.
Refractory disease: Mycophenolate mofetil and oral retinoids
Cho and colleagues (the same Stanford group as the Chiang LPPAI paper) reported on 16 patients with HCQ-refractory or severe LPP treated with mycophenolate mofetil. Roughly 83% had significant LPPAI reduction, with most of that reduction occurring within 6 months. MMF requires monitoring of CBC and LFTs and is reserved for patients failing first-line therapy because of its broader immunosuppressive profile.
Oral retinoids (acitretin, isotretinoin) have a smaller but real evidence base in LPP, with Spano and Donovan’s 2014 JAAD series describing efficacy in treatment-resistant disease. Acitretin is generally preferred for its keratinization-modulating profile and its precedent in lichenoid disorders, with the standard caveats around teratogenicity, lipid changes, and hepatic monitoring.
Newer evidence: Low-dose naltrexone
Strazzulla and colleagues published a small series in Journal of Drugs in Dermatology in 2017 reporting that low-dose naltrexone (3 mg daily) reduced pruritus and clinical activity in LPP. The mechanism is thought to involve toll-like receptor modulation and a modest anti-inflammatory effect via opioid receptor antagonism. The evidence base remains small, but LDN has the appeal of being inexpensive, well tolerated, and compatible with pregnancy planning, making it a reasonable add-on or alternative in selected patients. Lyakhovitsky and colleagues have published additional retrospective data through 2020–2023 supporting its role in cicatricial alopecia.
Emerging: JAK inhibitors
The mechanistic case for JAK inhibition in LPP is strong: JAK1/JAK3 signaling downstream of IFN-γ drives the lichenoid interface attack. Yang and colleagues published one of the earliest tofacitinib case series for LPP in Dermatologic Therapy in 2018, and Plante and colleagues followed in JAAD in 2020 with a retrospective review of tofacitinib in 10 LPP/FFA patients showing clinical improvement in the majority. The JAK-inhibitor literature in LPP remains case-series-level rather than randomized, but the FDA approvals of baricitinib, ritlecitinib, and deuruxolitinib for severe alopecia areata have created a regulatory pathway and clinical familiarity that the LPP literature is now beginning to leverage. Dose-finding and long-term safety in scarring alopecia remain open questions.
The therapeutic goal in LPP, as in FFA, is stabilization, not regrowth. The follicles that have already been replaced by fibrotic tracts will not return. Setting that expectation explicitly with a client at the first visit is one of the most therapeutic things you can do. Clients are often reading social-media accounts that describe LPP as “curable” with the right supplement stack. It is not. What it is, with appropriate stepwise treatment, is a disease that can be quieted to a level where most clients hold the hair they have for years to decades. That is the realistic, science-aligned promise.
Why LPP Belongs in Every Trichology Curriculum
LPP rewards the trichology skill set in a way that few other diseases do. It rewards listening: the client who reports burning and itching is the client who needs trichoscopy. It rewards seeing: perifollicular erythema and tubular scaling are visible to a trained eye long before bald patches consolidate. It rewards explaining: the client who understands that follicles are being permanently lost month by month is the client who agrees to early systemic therapy. And it rewards collaboration: a documented referral from a trichologist with photographs, LPPAI symptom inventory, and trichoscopic findings will get a dermatology appointment in two weeks where a vague self-referral might wait six months.
It also rewards humility. The LPP literature is overwhelmingly retrospective. Most of the agents on the treatment ladder are prescribed off-label. Randomized controlled trials in LPP can be counted on one hand. The 2024–2025 reviews continue to call for them. Until the evidence base catches up to the clinical need, the most defensible practice is the stepwise, mechanism-aligned approach the literature already supports: hydroxychloroquine first, pioglitazone or doxycycline second, MMF or retinoids in refractory disease, low-dose naltrexone as an adjunct, JAK inhibitors as the emerging frontier, and the LPPAI as the way you measure whether any of it is working.
What the trichologist contributes is not the prescription. It is the recognition. It is the language to explain the disease. It is the partnership with a dermatologist and the scaffolding of a treatment plan the client will actually adhere to over years. In a disease where the cosmetic outcome is determined by how early the active inflammation is quieted, the trichologist is often the person who decides whether a hairline still exists in five years.
The Bottom Line
Lichen planopilaris is a primary lymphocytic cicatricial alopecia driven by Th1/IFN-γ immune-privilege collapse at the follicular bulge, with PPAR-γ downregulation and JAK1/JAK3-STAT1 signaling as the central, therapeutically accessible pathways. The disease lives on a spectrum with FFA and Graham-Little-Piccardi-Lasseur syndrome and is closely related to fibrosing alopecia in a pattern distribution. The Chiang 2010 JAAD paper introduced the LPPAI, which remains the de facto outcome measure across the literature and showed that hydroxychloroquine 200 mg twice daily produces significant clinical improvement in roughly 69% of patients at 6 months and 83% at 12 months. Pioglitazone, repurposed from Karnik’s 2009 mechanism paper, is a defensible second-line with informed consent. Mycophenolate mofetil retains an 83% response rate in HCQ-refractory disease (Cho 2010). Low-dose naltrexone and JAK inhibitors (tofacitinib, with a small but mechanistically sound series base from Yang 2018 and Plante 2020) are the emerging additions. Trichoscopy is essential. Biopsy from the active patch edge is diagnostic. The therapeutic goal is stabilization, not regrowth. The trichologist’s highest-impact role is early recognition of the symptom-plus-perifollicular-erythema pattern and timely, well-documented referral to a dermatologist for systemic therapy, while the disease still has follicles left to save.